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Located within the brain’s ventricles, the choroid plexus produces
cerebrospinal fluid and forms an important barrier between the
central nervous system and the blood. For unknown reasons, the
choroid plexus produces high levels of the protein klotho. Here,
we show that these levels naturally decline with aging. Depleting
klotho selectively from the choroid plexus via targeted viral
vector-induced knockout in Klothoflox/flox mice increased the ex-
pression of multiple proinflammatory factors and triggered mac-
rophage infiltration of this structure in young mice, simulating
changes in unmanipulated old mice. Wild-type mice infected with
the same Cre recombinase-expressing virus did not show such al-
terations. Experimental depletion of klotho from the choroid
plexus enhanced microglial activation in the hippocampus after
peripheral injection of mice with lipopolysaccharide. In primary
cultures, klotho suppressed thioredoxin-interacting protein-dependent
activation of the NLRP3 inflammasome in macrophages by en-
hancing fibroblast growth factor 23 signaling. We conclude that
klotho functions as a gatekeeper at the interface between the
brain and immune system in the choroid plexus. Klotho depletion in
aging or disease may weaken this barrier and promote immune-
mediated neuropathogenesis.
aging | choroid plexus | inflammation | klotho | macrophage
Aging is associated with a progressive increase in in-flammatory alterations in the brain and other organs, a
process that has been dubbed “inflammaging” (1). Biomarkers of
inflammation are robust predictors of morbidity and mortality in
older humans (1) and of age-related cognitive decline (2). The
choroid plexus (CP) is an important gateway for the entry of
immune cells into the central nervous system (CNS) (3, 4). Lo-
cated within the ventricles of the brain, the CP consists of tight
junction-bound epithelial cells resting upon a basal lamina and
an inner stromal core. The stroma contains connective tissue and
large capillaries with thin fenestrated endothelial walls and can
harbor additional cell types, including dendritic cells with
antigen-presenting capacity, macrophages, and granulocytes (3–
5). The CP responds to signals from blood and cerebrospinal
fluid (CSF) and supports the CNS by producing CSF, nutrients,
and growth factors and by regulating pH, osmolality, ion con-
centrations, and immune molecule content in the extracellular
space of the brain and spinal cord (3–8). Throughout life, the CP
produces much higher levels of the antiaging protein α-klotho
(klotho) (9) than other components of the CNS [ref. 10 and the
Allen Brain Atlas (portal.brain-map.org)]. However, the func-
tions klotho fulfills in the CP remain to be defined.
Klotho production in peripheral organs is highest in the kidney
where it regulates vitamin D metabolism and the transport of
phosphate and calcium (8, 11). Alternative splicing gives rise to
two isoforms: secreted klotho (s-KL, amino acids 1 to 550 in
mice) and full-length transmembrane klotho (m-KL, amino acids
1 to 1014 in mice) (11). The latter can be cleaved by sheddases of
the ADAM family, resulting in proteolytic release of klotho (p-
KL, amino acids 1 to ∼960 in mice) into blood and CSF (11–13).
Klotho hypomorphic (kl/kl) mice have a deletion in the 5′ up-
stream region of the klotho gene, resulting in undetectable klotho
mRNA levels in organs that normally express the klotho gene,
such as the brain and kidney (9). While the possibility that the
klotho gene is slightly transcribed in these mutants remains, the
effect of this deletion is markedly reduced klotho expression
throughout the body and a premature aging phenotype that af-
fects multiple peripheral organs, resulting in early death (9, 14).
CNS alterations in kl/kl mice include hypomyelination, increased
expression or phosphorylation of neurofilaments, synaptic loss,
and behavioral impairments (14–16). Conceivably, at least some
of these alterations result from the global reduction of klotho
during early development and related systemic alterations. Whether
more circumscribed reductions of klotho later in life also cause CNS
pathology is not known. Here, we demonstrate that reducing klotho
levels selectively in the CP disrupts the barrier between the immune
system and the brain and promotes neuroinflammation.
Results
Aging Depletes Klotho in the CP. In brains of wild-type (WT) mice,
klotho was expressed predominantly in the CP (Fig. 1A and SI
Appendix, Fig. S1A) and to a lesser extent in the hippocampus (Fig.
1A and SI Appendix, Fig. S1A), consistent with previous reports (10,
17–19). Klotho levels in these structures were markedly reduced in
kl/kl mice (Fig. 1 B and C and SI Appendix, Fig. S1B). In the CP, a
130-kDa doublet band, most likely representing m-KL and p-KL,
was the predominant form of klotho detected by Western blot
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analysis (SI Appendix, Fig. S1 B and C) and will be referred to
simply as klotho. In the CP and hippocampus of WT mice, s-KL
(the short isoform) was undetectable at the protein level (SI Ap-
pendix, Fig. S1C); very low levels of s-KLmRNA were detected by
quantitative RT-PCR using isoform-specific primers (Fig. 1D).
Klotho levels decrease with age in the plasma and CSF of
humans (20), the white matter of monkeys (21), and the brain
and kidney of mice (22, 23); however, the effects of aging on
klotho expression in the CP appear to be unknown. In WT mice,
klotho levels in the CP were ∼34% lower at 26 mo of age than at
2 to 3 mo (Fig. 1E). This reduction was accompanied by an
∼32% decrease in m-KL mRNA levels (Fig. 1F), suggesting that
aging affects Klotho expression in the CP at the pretranslational
level. Although Massó et al. (23) found age-dependent reduc-
tions in hippocampal m-KL and s-KL mRNA levels in WT mice
of a different genetic background, aging did not affect the hip-
pocampal levels of klotho (SI Appendix, Fig. S1D) or Klotho
mRNA (SI Appendix, Fig. S1E) in our WT mice.
A
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
***
***
C
K
lo
th
o 
pr
ot
ei
n 
le
ve
l 
WT kl/kl
Choroid plexus
Exons 1-5 Exons 1-3
**
WT kl/kl
Hippocampus D
0-7
0-5
0-3
0-1
101
***
***
Choroid plexus
Hippocampus
1
1
1
1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
E
K
lo
th
o 
m
R
N
A 
le
ve
l 
F
Age (months)
2-3    7-9   26-30
Age (months)
2-3      26-30
Choroid plexus Choroid plexus
*
J
Klotho 
AE2
Flox/CreWT/Cre
n.s.
H
Choroid plexus
Flox/CreWT/Cre
Choroid plexus
Klotho
GAPDH
Flox/CreWT/Cre
Hippocampus
G
37
130
Flox/CreWT/Cre
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
I
**
Choroid plexus Hippocampus
Flox/CreWT/Cre Flox/CreWT/Cre
n.s.
Hippocampus
Flox/CreWT/Cre
*
K
lo
th
o 
pr
ot
ei
n 
le
ve
l 
K
lo
th
o 
pr
ot
ei
n 
le
ve
l 
K
lo
th
o 
pr
ot
ei
n 
le
ve
l 
K
lo
th
o 
pr
ot
ei
n 
le
ve
l 
K
lo
th
o 
m
R
N
A 
le
ve
l 
K
lo
th
o 
m
R
N
A 
le
ve
l 
K
lo
th
o 
m
R
N
A 
le
ve
l
B  Merge
kl
/k
l
W
T
AE2Klotho  
Fig. 1. Klotho depletion in the CP caused by aging or experimental manipulation. (A) CP (arrow) in the lateral ventricle of a 4-mo-old WT mouse visualized by
klotho immunostaining of a coronal brain section. (B) Images of confocal optical sections of CPs in the lateral ventricles of 4-mo-old WT and kl/kl mice
immunostained for klotho (green) and for the CP marker protein anion exchanger 2 (AE2). [Scale bars: 500 μm (A), 60 μm (B), 20 μm (B, Inset).] (C) Relative
klotho levels in 2-mo-old mice (C, E, and H) were measured by Western blotting, normalized to GAPDH levels, and expressed relative to mean levels in WT
controls. Relative Klotho mRNA levels (F and I) were calculated by the 2–ΔΔCT method (75) using Gapdh mRNA as the internal reference and WT mice as the
control. n = 11 to12 (CP) or 3 to 4 (hippocampus) mice per genotype. (D) Levels of Klotho mRNAs encoding the longer (exons 1 to 5) or shorter (exons 1 to 3)
isoform in 4-mo-old WT mice determined by RT-qPCR. n = 8 (CP) or 15 (hippocampus) mice per group. Note that a log-10 scale was used because of the large
differences in the levels of the Klotho transcripts. (E and F) CP levels of klotho protein (E) and Klotho mRNA (F) in WT mice. n = 13 mice per group. (G and H)
Western blot (G) and klotho levels (H) in 7- to 8-mo-old WT and Klothoflox/flox (Flox) mice determined 5 to 6 mo after i.c.v. injection of AAV5-CMV-Cre (Cre). n =
4 mice per group. (I) KlothomRNA levels in 20- to 24-mo-old WT and Klothoflox/flox (Flox) mice measured 11 mo after Cre injection (n = 4 to 8 mice per group).
(J) Sagittal CP sections colabeled for klotho (green) and anion exchanger 2 (AE2) (red) from 20- to 24-mo-old WT and Klothoflox/flox mice obtained 11 mo after
Cre injection. (Scale bars: 50 μm.) *P < 0.05, **P < 0.01, ***P < 0.001 vs. leftmost bar by unpaired, two-tailed t test (C, F, H, and I) or one-way ANOVA and
Tukey test (D and E). n.s., not significant. Values in bar graphs are means ± SEM.
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Klotho Reduction in the CP Does Not Alter Hippocampal Klotho Levels.
To investigate the function of klotho in the CP, we reduced klotho
levels specifically in this structure by intracerebroventricular (i.c.v.)
injection of a viral vector encoding Cre recombinase into mice
carrying two floxed Klotho alleles (Klothoflox/flox) (24). We used an
adeno-associated virus serotype 5 (AAV5)-CMV construct that
selectively targets expression to the CP upon i.c.v. injection (SI
Appendix, Fig. S2A). Mice injected with AAV5-CMV-Cre-GFP
(Cre) at 2 mo of age had ∼70% less klotho in the CP at 7 to
8 mo of age (Fig. 1 G and H) when klotho levels had not yet de-
creased in WT controls (Fig. 1E). The klotho reduction in the CP
of Cre-injected Klothoflox/flox mice was comparable with that in
uninjected kl/kl mice (Fig. 1C and ref. 9). Selective reduction of
klotho in the CP did not alter the gross morphology of this struc-
ture (SI Appendix, Fig. S2 B–D), the expression of the CP epithelial
cell markers anion-exchanger 2 (Fig. 1J), aquaporin-1, cytokeratin,
and CD31 (SI Appendix, Fig. S2 C and D), or the level and dis-
tribution of the tight junction protein claudin-1 (SI Appendix, Fig.
S2D). AAV5-driven Cre expression was confined to the CP (SI
Appendix, Fig. S2A) and reduced klotho levels similarly in the CPs
of the lateral and fourth ventricles in Klothoflox/flox mice (SI Ap-
pendix, Fig. S3 A and C). No Cre expression or klotho reduction
was detected in peripheral klotho-expressing tissues, such as the
kidney (SI Appendix, Fig. S3 B and D).
Because m-KL is expressed abundantly in the CP and can be
shed into the CSF as p-KL (12, 13, 17), it has been postulated
that the CP functions as an important source of klotho for the
brain parenchyma (17). However, klotho reduction in the CP did
not alter klotho levels in the hippocampus (Fig. 1 G–I), sug-
gesting that most, if not all, of the klotho in the hippocampus is
generated locally and that CP-derived p-KL either does not
reach the hippocampus or represents only a very small fraction of
its overall klotho levels. The likeliest sources of klotho in the
hippocampus are pyramidal neurons and dentate granule cells
although they express much less klotho than CP epithelial cells
(Fig. 1D, SI Appendix, Fig. S1B, and ref. 18).
Klotho Reduction Increases MHC II. Many aging-related alterations
in the brain and other organs appear to involve inflammation (1).
We therefore examined whether the reduced expression of klo-
tho in the CP of old mice was associated with an increased ex-
pression of inflammatory mediators. One such mediator is the
major histocompatibility complex class II (MHC II), whose ex-
pression by antigen-presenting cells in the brain increases with
age (25, 26). In the CP, aging-related increases in MHC II are
found primarily in antigen-presenting stromal cells, which have a
highly irregular and elongated shape (27). Because of this shape, it
can be difficult to differentiate between adjacent MHC II-positive
cells. Therefore, we examined percent area occupied by MHC II
immunoreactivity as a more reliable measure of MHC II expression
in the CP. Consistent with the findings by Baruch et al. (27), MHC II
immunoreactivity levels in the CP of uninjected WT mice were 5.6-
fold higher at 22 to 23 mo than at 2 to 3 mo of age, and MHC II-
positive cells were distinct from CP epithelial cells (Fig. 2 A–C).
To determine whether this increase in MHC II expression was
a cause or consequence of the associated klotho reduction, we
analyzed 19- to 22-mo-old WT and Klothoflox/flox mice 9 mo after
i.c.v. injection of Cre. Selective reduction of klotho in the CP
further increased MHC II expression in this structure by twofold
(Fig. 2 D and E), suggesting that klotho reduction increases
MHC II expression in the CP.
Klotho Regulates IFN-Related Genes. MHC II expression is regu-
lated by interferons (28, 29), a complex family of proteins and
peptides that induce the expression of cell-adhesion molecules
and other immunologically relevant cell membrane constituents,
control growth and differentiation, and activate natural killer
cells and macrophages (30). The expression of inflammatory
regulators and mediators is altered in the CP of aged mice, and
alterations in some of these factors can impair brain functions (3,
27, 31, 32). In the current study, we analyzed a selection of
factors that (i) are expressed in the CP, (ii) are altered by aging,
and (iii) represent diverse components of the innate immune
system (27, 31, 32).
In WT mice, aging markedly increased the expression of in-
tercellular adhesion molecule 1 (ICAM1) and IFN regulatory
factor 7 (IRF7) in the CP (SI Appendix, Fig. S4A). Selective
reduction of klotho in the CP of Klothoflox/flox mice also increased
CP levels of ICAM1 and IRF7 (Fig. 3 A–C) and of mRNAs
encoding ICAM1 (Icam1), IRF7 (Irf7), chemokine (C-C motif)
ligand 17 (Ccl17), C-X-C motif chemokine 10 (Cxcl10), and
CX3C chemokine receptor 1 (Cx3cr1) (SI Appendix, Fig. S4B).
ICAM1 expression was localized to the surface membrane of CP
epithelial cells, as demonstrated by double labeling of brain
sections for ICAM1 and transthyretin (Fig. 3D) or aquaporin 1
(AQP1) (Fig. 3E). In contrast, klotho reduction did not change
CP levels of mRNAs encoding IFN β (Ifnβ), TOLL-like receptor
9 (Tlr9), or IFN receptor 1 (Ifnar1) (SI Appendix, Fig. S4B).
Notably, Klothoflox/flox mice and WT controls were age- and
strain-matched and injected with the same Cre-expressing viral
construct. Furthermore, age-matched uninjected WT mice, Cre-
injected WT mice, and uninjected Klothoflox/flox mice had simi-
lar klotho levels in the CP (SI Appendix, Fig. S3A). It is there-
fore unlikely that differences between Cre-injected WT and
Cre-injected Klothoflox/flox mice resulted from mouse strain differences
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Fig. 2. Klotho depletion increases MHC class II expression in the CP. (A–D)
MHC II immunoreactivity in the CP of uninjected young (2 to 3 mo) vs. old
(22 to 23 mo) WT mice (A–C) and of Cre-injected 19- to 22-mo-old WT vs.
Klothoflox/flox (Flox) mice measured 9 mo after i.c.v. injection (D and E). n =
5 to 7 mice per group. Coronal CP sections were double-labeled for MHC II
(red) and for cytokeratin (gray) (A and D) or transthyretin (green) (B). [Scale
bars: 100 μm (A and D), 30 μm (B).] *P < 0.05, ***P < 0.001 by unpaired, two-
tailed t test. Values in bar graphs are means ± SEM.
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or from effects of the viral infection. Nevertheless, in uninfected
2-mo-old kl/kl mice, we confirmed that global genetic reduction of
klotho also increases the expression of IFN-related gene products
in the CP (SI Appendix, Fig. S5 A–C). Neither of these klotho
reduction strategies significantly altered the expression of such
gene products in the hippocampus (SI Appendix, Fig. S5 D and E).
Klotho Reduction Causes Macrophage Infiltration. The CP is an
important gateway for entry of immune cells into the CNS (3, 4,
33), and interferons can promote the transepithelial migration of
leukocytes through the CP (34). In light of our discovery that
klotho controls the expression of multiple immune mediators in
the CP, we further tested our hypothesis that klotho is a key
regulator of this gateway.
Cre-mediated klotho reduction increased the number of cells
bearing the macrophage markers MAC-2 or IBA-1 (Fig. 4 A–D)
in the CP of 19- to 22-mo-old Klothoflox/flox mice. These cells
were distinct from CP cells expressing transthyretin (Fig. 4C). To
investigate the origin of this macrophage population, we immu-
nostained the CP for lymphocyte antigen 6 complex (LY6C),
which is primarily expressed on blood-derived monocytes (35).
Klotho reduction in the CP increased the number of LY6C-
positive cells in this structure (Fig. 4 E and F), presumably by
increasing the production of immune modulators and chemo-
attractants by CP epithelial cells. The infiltration by putative
peripheral macrophages was associated with increased expres-
sion of macrophage-related gene products with pro- or antiin-
flammatory activities, including mRNAs encoding arginase 1
(Arg1), nitric oxide synthase 2 (Nos2), and complement C1Q A
chain (C1qα) (SI Appendix, Fig. S6 A–C). The CP of Cre-injected
Klothoflox/flox mice did not show significant changes in the num-
bers of T cells expressing CD3 or CD4 (SI Appendix, Fig. S6 D
and E). In contrast to Cre-injected Klothoflox/flox mice, uninjected
kl/kl mice showed no increases in the number of macrophages or
the expression of macrophage-related gene products in the CP
(SI Appendix, Fig. S7), although they had increased CP levels of at
least some of the immune modulators (SI Appendix, Fig. S5) whose
levels were increased in the CP of Cre-injected Klothoflox/flox
mice (SI Appendix, Fig. S4B and Table S1). Notably, kl/kl mice
were analyzed at 2 mo of age because of their short life span, whereas
Cre-injected Klothoflox/flox mice were analyzed between 18 and 24 mo
of age. Conceivably, the attraction of peripheral macrophages into
the klotho-depleted CP takes time, requires aging-related cofac-
tors that are missing in young kl/kl mice, or is counteracted by sys-
temic alterations in these mice.
Klotho Reduction in the CP Promotes Microglial Activation. To de-
termine whether klotho depletion from the CP affects other
parts of the brain, we focused on the hippocampus, which is
important for learning and memory and impaired by aging (36).
Microglia, the primary immune cells of the hippocampus, are
involved in neural plasticity, cognition, and neurological disease
(37). Aging sensitizes these cells to activation by peripheral in-
fections and lipopolysaccharide (LPS) injection, resulting in the
excessive release of cytokines and chemokines that can impair
cognitive functions (25, 38). To assess whether klotho reduc-
tion in the CP primes hippocampal microglia for activation, we
challenged a cohort of 19- to 22-mo-old Klothoflox/flox mice with
two i.p. injections of low-dose ultrapure LPS (1 mg/kg) or saline
9 mo after they received an i.c.v. injection of AAV5-CMV-Cre
(Cre) or AAV5-CMV-GFP (GFP). We then examined hippo-
campal levels of the microglial/macrophage marker IBA-1 and
the microglia-specific marker TMEM119 by fluorescence micros-
copy. Microglial activation is associated with increased IBA-1
MergeA
Fl
ox
/C
re
W
T/
C
re
B C Klotho IRF7 Merge
Transthyretin/ICAM1 AQP1/ICAM1/DAPI
ED
0
10
20
30
40
%
 a
re
a 
of
  I
C
AM
1 
im
m
un
or
ea
ct
iv
ity ***
WT/Cre Flox/Cre
Choroid plexus
0
2
4
6
8
10
IC
AM
1 
in
te
ns
ity
 ***
WT/Cre Flox/Cre
Choroid plexus
Fl
ox
/C
re
W
T/
C
re
Merge 
(4th Ventricle) 
Cytokeratin Klotho ICAM1
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to 22-mo-old WT vs. Klothoflox/flox (Flox) mice measured 9 mo after Cre injection. n = 5 to 7 mice per group. Sections of CP from the lateral ventricle (A–C) or
fourth ventricle (C, Rightmost images) were colabeled for cytokeratin (gray), klotho (green), and ICAM1 (red) (A) or klotho (green) and IRF7 (red) (C). (Scale
bars: 100 μm.) The percent of the cytokeratin-immunoreactive area that was also positive for ICAM1 was quantitated in B. (D and E) High magnification
confocal images of the CP labeled for ICAM1 (red) and transthyretin (green) (D) or AQP1 (green) (E). [Scale bars: 25 μm (D), 50 μm (E).] ***P < 0.001 by
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expression, retraction of processes, and enlargement of cell bodies
(39). Both IBA-1 and TMEM119 immunostaining revealed mor-
phological changes typical of microglial activation in the hippo-
campus of LPS-injected mice (Fig. 5A). Klotho reduction in the
CP increased the number of IBA-1–positive cells (Fig. 5B) and the
level of IBA-1 intensity (Fig. 5C) in the hippocampus after LPS
injection. It also decreased the hippocampal TMEM119/IBA-
1 area ratio in LPS-treated mice (Fig. 5D), suggesting retraction of
microglial processes. These results indicate that klotho reduction
in the CP exacerbates LPS-induced microglial activation, possibly
through the release of inflammatory mediators from peripheral
macrophages that have invaded the CP and from cells that nor-
mally reside in this structure, such as antigen-presenting cells.
Klotho Controls the NLRP3 Inflammasome. To unravel how klotho
suppresses inflammation in the CP and other brain regions, we
turned our attention to its role in controlling the production of
vitamin D3 and of thioredoxin-interacting protein (TXNIP) (also
known as vitamin D3 up-regulated protein 1). In peripheral tis-
sues, klotho (m-KL > p-KL) functions as an obligate coreceptor
for fibroblast growth factor 23 (FGF23) (40), which is present in
blood and can be expected to traverse the fenestrated endothe-
lial walls of CP capillaries. Thus, similar to klotho released from
CP epithelial cells, blood-derived FGF23 should be able to in-
teract with FGF receptors on macrophages that have infiltrated
the stroma of the CP.
The FGF23/klotho signaling pathway suppresses the expression
of 1-α-hydroxylase, which converts 25-hydroxycholecalciferol
(25-VD3) into 1,25-dihydroxycholecalciferol (1,25-VD3 or cal-
citriol), the bioactive form of vitamin D, and increases the ex-
pression of 24-hydroxylase, which promotes the degradation of
1,25-VD3 (11, 40, 41). 1,25-VD3 can increase the expression of
TXNIP, which promotes activation of the nucleotide binding olig-
omerization domain-like receptor protein 3 (NLRP3) inflamma-
some and increases oxidative stress by inhibiting thioredoxin activity
(42–45). Since 1-α-hydroxylase is expressed in many cell types, in-
cluding epithelial cells and activated macrophages (46), we hy-
pothesized that klotho normally controls 1,25-VD3 production in
the CP and thereby suppresses TXNIP expression in cells that reside
within or can infiltrate this structure.
Compared with controls, Cre-injected Klothoflox/flox mice and
uninjected kl/kl mice had increased CP levels of Cyp27b1 mRNA
(Fig. 6 A and B), which encodes 1-α-hydroxylase. Both groups of
mice also had increased levels of Txnip mRNA and TXNIP
protein in the CP (Fig. 6 C–G), suggesting that klotho in the CP
may control the production of inflammatory mediators and the
entry of immune cells by suppressing local 1,25-VD3 production
and downstream inflammasome activation by TXNIP.
In contrast, Txnip mRNA levels in the hippocampus of Cre-
injected Klothoflox/flox mice and uninjected kl/kl mice were not sig-
nificantly different from those of their respective control littermates
(SI Appendix, Fig. S8 A and B). Txnip mRNA levels in the kidney
were also normal in kl/kl mice, despite profound reductions of
klotho in this organ (SI Appendix, Fig. S8 C and D). These
findings suggest that klotho has an important role in controlling
Txnip expression in some cell types, but not others. In kl/kl
mice, in which klotho levels are reduced during early devel-
opment, this function of klotho may also be obscured by
compensatory mechanisms.
Although macrophages do not appear to express full-length
transmembrane klotho (47), their biological activity could be
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altered by klotho released from other cells (40). To further dis-
sect the mechanisms by which klotho released from CP epithelial
cells might control NLRP3 activation in macrophages, we ex-
posed cultures of primary bone marrow-derived macrophages to
recombinant klotho (p-KL) and other immune modulators. NLRP3
is a sensitive innate immune sensor that is activated by diverse stress
signals (48). Its activation increases caspase 1 activity, resulting
in the release of potent immune mediators, such as interleukin-1β
(IL-1β), that may link inflammation to cognitive decline in aging (49).
To activate NLRP3, we treated macrophage cultures with LPS
and ATP (50). As expected, this treatment markedly increased IL-1β
levels in the medium of macrophages from WT mice, but not of
macrophages from Nlrp3−/− or Casp1/4−/−mice (SI Appendix, Fig. S9),
which lack NLRP3 (51) or caspases 1 and 4 (52, 53), respectively.
Pretreatment of macrophages with 1,25-VD3, or with its immediate
precursor, 25-VD3, enhanced the LPS/ATP-induced macrophage
activation (Fig. 6H), consistent with previous findings (54).
Pretreatment of macrophages with a combination of klotho
and FGF23 blocked the vitamin D3-induced enhancement of IL-
1β release (Fig. 6H) whereas klotho or FGF23 alone had no
significant modulatory effects (Fig. 6H). Interestingly, FGF23/
klotho blocked the enhancement of LPS/ATP-induced IL-1β
release by both 25-VD3 and 1,25-VD3 (Fig. 6H). This result
suggests that FGF23/klotho signaling suppresses NLRP3 activa-
tion, not only by reducing the expression of 1-α-hydroxylase (Fig. 6
A and B), which generates 1,25-VD3 from 25-VD3, but also by
counteracting 1,25-VD3 downstream, possibly by promoting its
degradation or blocking its effect on Txnip expression. Thus,
FGF23/klotho signaling suppresses 1,25-VD3–dependent inflam-
masome activation in macrophages, and depletion of klotho from
the CP may increase the release of proinflammatory cytokines by
infiltrating macrophages, which—in turn—could attract addi-
tional macrophages from the periphery and prime microglia in
the brain parenchyma for activation (Fig. 5).
Discussion
Our findings suggest that klotho in the CP functions as a gate-
keeper between the immune system and the CNS. The high level
of klotho expressed in the CP of juvenile and adult mice, hu-
mans, and other mammals probably limits the penetration of this
barrier by peripheral immune cells and suppresses the pro-
duction of inflammatory mediators that could harm the CNS.
We found that Klotho expression in the CP decreases with age
and that experimental reduction of klotho levels specifically in
this structure promotes the entry of peripheral macrophages and
markedly increases the production of multiple proinflammatory
mediators. Because similar proinflammatory changes occur dur-
ing the natural aging process, the age-related decline in Klotho
expression may contribute to the aging-related inflammation of the
CNS. Because the CP produces and is bathed in CSF, inflamma-
tory mediators produced in the CP are likely to reach other parts
of the CNS via the CSF circulation (55), including the parenchyma
of the brain and spinal cord, where they might contribute—by
themselves or in combination with other factors—to the aging-
related decline in neural functions (56). Indeed, experimental re-
duction of klotho in the CP exacerbated microglial activation in the
hippocampus following peripheral injections of relatively low doses
of LPS in the current study, suggesting that klotho depletion from
the CP could contribute to the age-dependent “priming” of micro-
glia for activation by peripheral infections (25, 38). Microglial acti-
vation and elevated IL-1β have been associated with deficits in
synaptic plasticity in the hippocampus (57).
A more detailed comparison of the results we obtained after
experimentally reducing klotho levels in the CP of mice to those
reported to spontaneously develop in the CP of aged mice re-
veals both similarities and differences. For example, klotho re-
duction in the CP increased the expression of IRF7, a key
regulator of type I IFN (IFNα/β) responses, which have impor-
tant roles in adaptive and innate immunity (58). IRF7 is also
increased in the CP of aged mice and humans (32). In a similar
vein, arginase-1 expression in the CP was increased in mice with
selective klotho reduction in the CP (this study) as well as in aged
mice (27). In contrast, we found increased levels of Icam1, Cxcl10,
and Ccl17 mRNAs and of ICAM1 protein in the CP of mice with
reduced klotho expression, whereas others found decreased levels
of these gene products in the CP of aged mice (32). Some of these
differences may reflect the fact that processes other than klotho
reduction also affect the CP during aging and may override
changes caused by klotho depletion. Other differences may have
methodological or other reasons. For example, Baruch et al.
reported increased IRF7 but decreased ICAM1 levels in the CP of
aged mice (32), whereas CP levels of both proteins were increased
in our aged mice, consistent with the results we obtained after
reducing klotho levels in the CP of Klothoflox/flox mice by
Cre injection.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
B
WT        kl/kl
Choroid plexus
* TXNIP
Klotho
GAPDH
C
130
44
37
Flox/CreWT/Cre
0.0
0.5
1.0
1.5
2.0
2.5
C
yp
27
b1
 m
R
N
A 
le
ve
l 
Choroid plexus
Flox/CreWT/Cre
A
*
C
yp
27
b1
 m
R
N
A 
le
ve
l 
0
1
2
3
4
5
6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
E
*
Choroid plexus
F
 T
xn
ip
 m
R
N
A 
le
ve
l 
Flox/CreWT/Cre
TX
N
IP
 p
ro
te
in
 le
ve
l 
WT        kl/kl
Choroid plexus
*
0.0
0.5
1.0
1.5
2.0 ***
G
Choroid plexus
 T
xn
ip
 m
R
N
A 
le
ve
l 
WT       kl/kl
D
 T
X
N
IP
 p
ro
te
in
 le
ve
l 
Choroid plexus
Flox/CreWT/Cre
0.0
0.5
1.0
1.5
2.0
2.5
3.0
*
H
0.0
0.5
1.0
1.5
2.0
2.5
IL
-1
 le
ve
l
LPS-ATP
25-VD3 (nM)
1,25-VD3 (nM)
Klotho (ng/ml)
FGF23 (ng/ml)
+
-
-
-
-
+
100
-
-
-
+
100
-
500
10
+
100
-
500
100
*
***
**** ***
+
-
10
+
-
10
500
100
+
100
-
10
+
100
-
100
+
100
-
50
+
100
-
500
- -
- - -
-
**
Fig. 6. Klotho controls regulators of the NLRP3 inflammasome. (A and B) CP
levels of Cyp27b1 mRNA in 20- to 24-mo-old WT vs. Klothoflox/flox (Flox) mice
(n = 8 to 9 per group) measured 9 mo after Cre injection (A) and in unin-
jected 2-mo-old WT vs. kl/klmice (n = 12 per group) (B). (C–G) Levels of TXNIP
(C, D, and F) and klotho (C) protein and of Txnip mRNA (E and G) in 7- to 8-
mo-old (C and D) or 20- to 24-mo-old (E) WT vs. Klothoflox/flox (Flox) mice (n =
4 per group) measured 5 (C and D) or 11 (E) mo after Cre injection and in
uninjected 2-mo-old WT vs. kl/kl mice (n = 12 per group) (F and G). Relative
protein and mRNA levels were determined as described in Fig. 1H. (H) Rel-
ative IL-1β levels in culture medium of bone marrow-derived primary mac-
rophages from WT mice determined by ELISA on days in vitro 7 to 10 after
treatment with LPS (100 EU/mL for 20 h; start time: 0 h) and ATP (1 mM for
1 h; start time: 20 h). Cultures were pretreated by adding vehicle or one or
more of the following: 25-VD3 (time: −1 h), 1,25-VD3 (time: −1 h), klotho
(time: −2 h), FGF23 (time: −2 h). n = 4 independent experiments, each of
which included three to four wells per condition. IL-1β levels measured after
pretreatment with vehicle and LPS/ATP stimulation were defined as 1.0. *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. leftmost bar or as indicated
by brackets (one-way ANOVA and Bonferroni test). Values in bar graphs are
means ± SEM.
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Our study provides insights into the mechanisms by which
klotho may control the immune system/CNS interface in the CP.
In combination, our in vivo and in vitro data support the hy-
pothesis that klotho produced by CP epithelial cells suppresses
the activation of the NLRP3 inflammasome in macrophages and
possibly other cells, including the CP epithelial cells themselves,
through FGF23/klotho signaling, counteracting 1,25-VD3, and
inhibiting 1,25-VD3–dependent Txnip expression. TXNIP, which
was increased in the CP after klotho reduction, can directly in-
crease the expression of proinflammatory gene products that
promote leukocyte infiltration into the CNS, including ICAM-1
(59). TXNIP also promotes activation of the NLRP3 inflam-
masome, a process that probably contributes causally to multiple
aging-related deficits and aging-related diseases, including cog-
nitive decline and neurodegenerative disorders (49, 60).
Although TXNIP-dependent activation of the NLRP3 inflam-
masome is a plausible mechanism for many of the effects of klotho
reduction we observed, our study was not designed to exclude
alternative mechanisms by which klotho reduction in the CP might
contribute to aging-related alterations of the CNS (5). Both klotho
and the CP probably have diverse functions (3, 4, 6, 11, 33, 61).
For example, klotho also attenuates the NF-κB pathway (62),
which could contribute to the increase in ICAM1 expression after
klotho reduction. Similarly, increased expression of TXNIP could
affect multiple processes besides inflammation (42, 45). Another
limitation of our study is that we did not systematically compare
the effects of klotho reduction in CPs of all ventricles, which share
many but not all properties (6).
In contrast to the genetic reduction of klotho in kl/kl mice, the
injection of a Cre-expressing viral vector into Klothoflox/flox mice
allowed us to (i) restrict klotho reduction specifically to the CP,
(ii) avoid potential confounding effects of klotho reduction
during early development, and (iii) lower klotho levels at distinct
time points. Surprisingly, the viral vector approach revealed that
klotho production by the CP is not needed to maintain normal
klotho levels in the brain parenchyma, at least not in the hippo-
campus, where neurons produce low levels of klotho (18).
Despite the distinct ways in which klotho levels were reduced
in the two models, we confirmed in uninjected kl/kl mice several
of the findings we obtained in Cre-injected Klothoflox/flox mice,
highlighting the robustness of these findings. Alterations of the
CP observed in both models included increased levels of Cyp27b1
mRNA, Txnip mRNA, and mRNAs encoding IFN-related factors,
such as ICAM1, CCL17, and CXCR1. However, some changes we
observed in Cre-injected Klothoflox/flox mice between 18 and 24 mo
of age were not seen in uninjected kl/kl mice at 2 mo of age,
including increased numbers of MAC-2- and Ly6C- positive
cells and increased expression of the macrophage markers Nos2
and Arg1 in the CP. It is conceivable that these changes emerge
over time, require aging-related cofactors that are missing in
young kl/kl mice, or are prevented in kl/kl mice by the activation of
compensatory processes during early development.
Increased numbers of monocytes, macrophages, and T cells
have been identified in the kidneys of heterozygous Klotho hy-
pomorph (kl/+) mice (63). Our kl/kl mice had elevated TXNIP
levels in the CP but not in the kidney. The latter discrepancy may
reflect differences in cell type-specific inflammatory mecha-
nisms, as reported for NLRP3 and receptors on macrophages
and epithelial cells (64).
Reduced klotho levels and increased IL-1β levels have also
been observed in the CP of rats exposed to chronic unpredictable
stress, an experimental paradigm that causes behavioral alterations
in rodents reminiscent of endogenous depression in humans (19).
IL-1β also elicits depression-related behaviors in rodents (65). Our
findings may also be relevant to Alzheimer’s disease, in which
klotho levels are decreased in the CSF (20, 23) and brain inflam-
mation may have a critical pathogenic role (66–68).
Interestingly, global vitamin D3 deficiency is a risk factor for
age-related cognitive decline (69). Since vitamin D3 has diverse
effects throughout the body (69), it is tempting to speculate that
high levels of klotho in the CP curtail immune invasion of the
CNS via this important gateway by locally counteracting vitamin
D3 through FGF23/klotho signaling and reducing IFN/NLRP3-
related gene expression, enabling the organism to benefit from
useful vitamin D3 effects elsewhere. Further investigation of
klotho’s immune-regulatory roles in the CP may identify thera-
peutic strategies to block entry of harmful cells and factors into
the CNS through the blood–CSF barrier, which might help
counteract cognitive decline in elderly people and inflammaging-
related neurological disorders.
Methods
Mice and Treatments. Klothoflox/+ mice (24) were interbred to generate
Klothoflox/flox and Klotho+/+ littermates on the same C57BL/6J background.
CP-specific ablation of Klotho in Klothoflox/flox mice was achieved by ste-
reotaxically injecting 2 μL of high-titer (1 to 10 × 1012/mL) AAV5-CMV-Cre-
GFP (AAV5.CMV.HI.Cre.WPRE.SV40; Virovek) into the left lateral ventricle
[coordinates: −1 mm mediolateral (M/L), −0.22 mm anteroposterior (A/P),
and −2.5 mm dorsoventral (D/V) from the bregma]. Stereotaxic injections
were carried out as described (70). WT mice injected with AAV5-CMV-Cre-
GFP and in some cases Klothoflox/flox mice injected with AAV5-CMV-GFP
(AAV5.CMV.HI.eGFP.WPRE.SV40; Virovek) served as negative controls. Over-
expression of klotho in the hippocampus was achieved by injection of lentivirus
encoding full-length klotho (Lenti-FUW2-klotho) into the dentate gyrus and
CA1. The kl/klmouse line (9) was obtained fromM. Kuro-o (National Institute of
Neuroscience, Kodaira, Tokyo) and the Nlrp3−/− line (51) from A. Ma (University
of California, San Francisco, CA) Casp1/4−/− mice (52) were obtained from The
Jackson Laboratory (strain 16621). Some mice received two separate i.p. injec-
tions of LPS (1 mg/kg; LPS-055: EB5; InvivoGen) 20 h apart and were perfused as
described below 4 h after the second injection. Experimental and control
groups were age-matched and littermates. Mice were maintained on a 12-h
light/dark cycle, and experiments were conducted during the light cycle. Mice
had free access to food (PicoLab Rodent Diet 20, 5053; LabDiet) and water,
were housed 2 to 5 per cage. All procedures were approved by the Institutional
Animal Care and Use Committee of the University of California, San Francisco.
Isolation of Mouse Tissues. Mice were anesthetized with Avertin (0.025 mg/mL)
and perfused transcardially with 0.9% saline. Hemibrains were removed and
drop-fixed in 4% paraformaldehyde overnight at 4 °C or flash-frozen in liquid
nitrogen and stored at −80 °C. Frozen hemibrains were thawed in cold 1× PBS
containing Halt Protease and Phosphatase Inhibitor Mixture (78447; Thermo
Fisher Scientific) and microdissected immediately. The intact choroid plexus
(CP) was removed first to avoid contaminating other tissues. Microdissected
tissues were immediately frozen on dry ice and kept at −80 °C.
Primary Macrophage Cultures. Primarymacrophages were prepared from 3- to
5-mo-old WT C57BL/6J mice as described (71). Femur bone marrow was
extracted and mechanically dissociated in RPMI-1640 medium (Life Tech-
nologies). The cells were cultured in RPMI-1640, 10% FBS, 20 mM penicillin/
streptomycin and 20 ng/mL macrophage colony-stimulating factor (ProSpec)
at 2 × 106 cells per non-TC grade sterile 100-mm Petri dish (Corning). After
3 d, cells were dissociated in ice-cold PBS and replated in 12-well plates at 1 ×
105 per well. Experiments were done on confluent cultures (typically days in
vitro 7 to 8). Cultures were treated with ultrapure LPS (104 units/mL) for
16 to 24 h and harvested for analysis. Some cultures were incubated for an
additional 4 h with ATP (1 mM; Sigma). In some cases, recombinant klotho
(R&D Systems) and FGF-23 (R&D Systems) were added 1 h before LPS. After
treatment, cells were washed once with PBS and collected for protein or
mRNA analysis.
Immunohistochemistry. Brain sections were prepared and immunostained as
described (72–74). Briefly, hemibrains were drop-fixed in 4% paraformaldehyde
overnight, washed in cold PBS, equilibrated in 30% sucrose for ≥48 h, and
stored at 4 °C. Hemibrains were sectioned (30 μm) on a freezing microtome,
immunostained, and imaged with a digital microscope (BZ-9000; Keyence) or a
laser-scanning microscope (LSM 880; Zeiss). Except for MHC II, antigen retrieval
was performed using 10mM citrate buffer at 105 °C for 20 min. After cooling at
room temperature for at least 45 min, sections were incubated with 3% H2O2
for 15 min to quench endogenous peroxidase, washed four times in PBS, in-
cubated in blocking/permeabilization solution containing 10% normal goat
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serum and 0.3% Triton-X in PBS for ≥45 min, and incubated for ≥24 h with
primary antibodies in 5% normal goat serum and 0.1% Triton X-100 in PBS at
room temperature (dilutions provided in SI Appendix, Table S2). After three
washes in PBS, sections were incubated with secondary antibodies (1:500;
Invitrogen) and Hoechst 33342 (H33570; Thermo Scientific) diluted in 2% nor-
mal goat serum and 0.1% Triton X-100 in PBS for 2 h at room temperature.
CLAUDIN-1 was detected with TSA-Plus cyanine 5 kits (PerkinElmer). Negative
controls included omission of primary or secondary antibodies. High-resolution
imaging was done with a Zeiss LSM 880 or a Keyence BZ-9000 automated mi-
croscope system. The Zeiss LSM 880 inverted scanning confocal microscope (Carl
Zeiss Microscopy) was equipped with two photomultiplier tube (PMT) detectors,
a high-sensitivity Gallium arsenide phosphide (GaAsP) detector, and a 32-GaAsP
Airyscan superresolution detector and run by Zeiss Zen imaging software. The
Keyence BZ-9000 inverted epifluorescence microscope was equipped with a 12-
bit monochrome camera with red, green, and blue (RGB) capability. Unless
indicated otherwise, all CP images were from CP in the lateral ventricles. For
confocal microscopy, images were taken in z-stacks (2- to 4-μm steps) through
immunoreactive areas. Z-stacks were analyzed with ImageJ or with Imaris
software (Bitplane). For each section, numbers of cells positive for IRF7, ICAM1,
MAC-2, or LY6C in the CP were normalized to the CP area in any given section;
two to five sections were analyzed per mouse, and positive cells per area were
averaged to generate a single value for each mouse (n). For quantitation of
IBA-1 immunoreactivities, sections were stained as described above and imaged
on a Versa Slide Scanner (Leica Systems) in z-stacks of 2-μm steps. The images
were then batch-processed and analyzed using a macro developed in-house
and the following functions. Areas of TMEM119 and IBA-1 immunoreactivity
were measured by applying an adaptive threshold function (https://sites.google.
com/site/qingzongtseng/adaptivethreshold). IBA-1–positive cells were counted
automatically in the same images using the analyzed particle function
of ImageJ.
Western Blotting. CPs from the fourth and lateral ventricles were combined
for each mouse (except for SI Appendix, Fig. S3 in which they were analyzed
separately), homogenized in radioimmunoprecipitation assay (RIPA) buffer
containing Halt Protease and Phosphatase Inhibitor Mixture (Thermo Sci-
entific), and sonicated (Episonic 1000; Epigentek) at amplitude 40 for 5 min;
protein concentrations were determined by the bicinchoninic acid (BCA)
method. Equal amounts of total protein (10 to 20 μg for CP and 20 to 30 μg
for hippocampus and kidney) were loaded in 1× NuPAGE LDS sample buffer
(NP0007; Thermo Fisher Scientific) and 1× Sample Reducing Agent (NP0009;
Thermo Fisher Scientific), separated on NuPAGE 4 to 12% Bis‐Tris gels
(WT1403A; Thermo Fisher Scientific) at 200 V for 1.0 to 1.5 h in ice-cold 1×
NuPAGE MOPS SDS running buffer (NP0001-02; Thermo Fisher Scientific).
Gels were wet-transferred to nitrocellulose membranes (16 h, 25 V). The
blots were then blocked with Odyssey Blocking Buffer (927-40000; LI-COR)
for 1 h at room temperature, incubated with primary antibodies (SI Ap-
pendix, Table S2) overnight at 4 °C, washed with PBS containing 0.05%
Tween 20 (PBST) three to four times for 5 min at room temperature, in-
cubated with secondary antibodies conjugated to IRDye (0.1 μg/mL; Li-COR)
for 1 h at room temperature, and washed in PBST three to four times for
5 min at room temperature. Protein bands were visualized with an Odyssey
CLx Infrared Imaging System (LI-COR) and quantified with Image Studio
Software (LI-COR) following the manufacturer’s instructions. The mean tar-
get protein:GAPDH ratio in WT mice was defined as 1.0.
Quantitative Real-Time RT-PCR. Total RNA from mouse CPs from lateral and
fourth ventricles or hippocampus was isolated with RNeasy Kits (74106;
Qiagen) and reverse-transcribed with High-Capacity cDNA Reverse Tran-
scription Kits (Thermo Fisher Scientific). After reverse transcription, quanti-
tative real-time PCR was conducted with an ABI Prism 7900HT Sequence
Detection System and SYBRGreenNucleic Acid Detection Kit or TaqManGene
Expression Master Mix (Thermo Fisher Scientific) and TaqMan primers (Ap-
plied Biosystems) (SI Appendix, Table S3). Levels of each target mRNA were
detected with FAM dye. Normalized relative target mRNA levels were cal-
culated by the 2–ΔΔCT method (75) using GAPDH mRNA levels (detected with
VIC dye in the same well) as the internal reference and expressed relative to
mean values in the control group. Primer sequences used to detect tran-
scripts encoding distinct klotho isoforms with the SYBR Green PCR method
are shown in SI Appendix, Table S4.
Statistical Analysis. Prism (version 5; GraphPad), R (R Development Core Team,
www.R-project.org/), and Microsoft Excel were used for statistical analyses.
“n” refers to the number of mice for all figures except Fig. 6, in which “n”
refers to independent experiments. Differences between genotypes and
treatments were assessed by unpaired, two-tailed t test with Welch’s cor-
rection or by one-way or two-way ANOVA and Bonferroni, Holm-Sidak, or
Tukey post hoc tests. P < 0.05 was considered significant. Results were col-
lected blinded to genotype and treatment of mice and cell cultures. Bi-
ological units were randomized during assays, sampling, and analysis.
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